Abstract
This IDC Study represents the opportunity for selling information technology infrastructure into the bioscience or, as IDC calls it, life sciences
marketplace. In quantifying the life sciences infrastructure market, IDC is focused on the IT solution set required to support biological and chemical
workloads. This forecast considers workloads that are associated with the drug-discovery process or product development, including basic research,
genomics, proteomics, and other emerging applications, through those that support all aspects of the clinical trials process.
While much of the near-term focus is on the pharmaceutical and biotech industries, IDC has extended its view to include companies playing in other
bioscience arenas, such as contract research organizations (CROs) and agricultural science companies. "In today's dampened economy, few
technology markets can boast growth as impressive as that which IDC sees in the Life Sciences market in the region. The market remains a bright spot
for hardware, software, and services vendors alike because of continued investment by large pharmaceutical and biotech companies," said Daphne
Chung, Senior Analyst, Life Sciences and Healthcare, IDC Asia/Pacific.
This market sizing and forecast improves on the preliminary published IDC market size and forecast for the market in terms of product segments such
as hardware, software, and services, significant end user segments as defined by IDC and sub-regional information in Asia/Pacific. The study includes
key points and trends in the region for this market from end user studies carried out by IDC.
View Cart
